Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate of 9%. Major obstacles to successful treatment of pancreatic cancer are the immunosuppressive tumor microenvironment (TME) and antigenic complexity or heterogeneity. Programmed death-ligand 1 (PD-L1) is expr...

Full description

Bibliographic Details
Main Authors:	Ching-Yao Yang, Ming Huei Fan, Carol H. Miao, Yi Jen Liao, Ray-Hwang Yuan, Chao Lien Liu
Format:	Article
Language:	English
Published:	Elsevier 2020-06-01
Series:	Molecular Therapy: Oncolytics
Subjects:	PD-1 PD-L1 ACR CAR PDAC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2372770520300723

Similar Items

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
by: Huilin Ou, et al.
Published: (2022-08-01)

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
by: Zeping Wang, et al.
Published: (2024-10-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
by: Ugochi Ebinama, et al.
Published: (2023-11-01)

Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
by: Linus Winter, et al.
Published: (2024-09-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
by: Qing Tang, et al.
Published: (2022-09-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer
by: Hao-Chien Hung, et al.
Published: (2023-09-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
by: Domenico Ribatti, et al.
Published: (2024-07-01)

Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers
by: Paulina Poter, et al.
Published: (2024-05-01)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
by: Hashem O. Alsaab, et al.
Published: (2017-08-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1  Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis
by: Jiamin SHENG, et al.
Published: (2020-11-01)

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
by: Crescenzo D’Alterio, et al.
Published: (2022-10-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)

PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105
by: Xi Wang, et al.
Published: (2023-01-01)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
by: Siqing Jiang, et al.
Published: (2022-09-01)